Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Tipo de estudo
Intervalo de ano de publicação
1.
Clin Exp Immunol ; 204(1): 125-133, 2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-33314126

RESUMO

The United Kingdom has a national immunization programme which includes annual influenza vaccination in school-aged children, using live attenuated influenza vaccine (LAIV). LAIV is given annually, and it is unclear whether repeat administration can affect immunogenicity. Because LAIV is delivered intranasally, pre-existing local antibody might be important. In this study, we analysed banked samples from a study performed during the 2017/18 influenza season to investigate the role of pre-existing influenza-specific nasal immunoglobulin (Ig)A in children aged 6-14 years. Nasopharyngeal swabs were collected prior to LAIV immunization to measure pre-existing IgA levels and test for concurrent upper respiratory tract viral infections (URTI). Oral fluid samples were taken at baseline and 21-28 days after LAIV to measure IgG as a surrogate of immunogenicity. Antibody levels at baseline were compared with a pre-existing data set of LAIV shedding from the same individuals, measured by reverse transcription-polymerase chain reaction. There was detectable nasal IgA specific to all four strains in the vaccine at baseline. However, baseline nasal IgA did not correlate with the fold change in IgG response to the vaccine. Baseline nasal IgA also did not have an impact upon whether vaccine virus RNA was detectable after immunization. There was no difference in fold change of antibody between individuals with and without an URTI at the time of immunization. Overall, we observed no effect of pre-existing influenza-specific nasal antibody levels on immunogenicity, supporting annual immunization with LAIV in children.


Assuntos
Anticorpos Antivirais/imunologia , Imunogenicidade da Vacina/imunologia , Imunoglobulina A/imunologia , Vacinas contra Influenza/imunologia , Influenza Humana/imunologia , Cavidade Nasal/imunologia , Administração Intranasal , Adolescente , Criança , Feminino , Humanos , Imunoglobulina G/imunologia , Vírus da Influenza A Subtipo H1N1/imunologia , Vírus da Influenza A Subtipo H3N2/imunologia , Vacinas contra Influenza/administração & dosagem , Influenza Humana/prevenção & controle , Influenza Humana/virologia , Masculino , Cavidade Nasal/virologia , Vacinação/métodos , Vacinas Atenuadas/administração & dosagem , Vacinas Atenuadas/imunologia , Eliminação de Partículas Virais/imunologia
2.
Clin Exp Immunol ; 199(2): 109-118, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-31670841

RESUMO

Different vaccine strains included in the live attenuated influenza vaccine (LAIV) have variable efficacy. The reasons for this are not clear and may include differences in immunogenicity. We report a Phase IV open-label study on the immunogenicity of a single dose of quadrivalent LAIV (Fluenz™ Tetra) in children during the 2015/16 season, to investigate the antibody responses to different strains. Eligible children were enrolled to receive LAIV; nasal samples were collected before and approximately 4 weeks after immunization. There was a significant increase in nasal immunoglobulin (Ig)A to the H3N2, B/Victoria lineage (B/Brisbane) and B/Yamagata lineage (B/Phuket) components, but not to the H1N1 component. The fold change in nasal IgA response was inversely proportional to the baseline nasal IgA titre for H1N1, H3N2 and B/Brisbane. We investigated possible associations that may explain baseline nasal IgA, including age and prior vaccination status, but found different patterns for different antigens, suggesting that the response is multi-factorial. Overall, we observed differences in immune responses to different viral strains included in the vaccine; the reasons for this require further investigation.


Assuntos
Anticorpos Antivirais/imunologia , Imunização , Imunoglobulina A/imunologia , Vírus da Influenza A Subtipo H1N1/imunologia , Vírus da Influenza A Subtipo H3N2/imunologia , Vacinas contra Influenza/administração & dosagem , Cavidade Nasal/imunologia , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Masculino , Vacinas Vivas não Atenuadas/administração & dosagem
3.
Med J Aust ; 1(11): 585-6, 1981 May 30.
Artigo em Inglês | MEDLINE | ID: mdl-7254038

RESUMO

The clinical record of a patient who suffered a mid-trimester missed abortion during an acute febrile illness is presented. Campylobacter jejuni was isolated from her blood cultures. Complete clinical recovery followed evacuation of the uterus and antibiotic therapy. Evidence of placental infection was found on histological examination. The possible role of campylobacter and other infections in fetal and perinatal death is discussed.


PIP: This case report of a 23-year-old woman who suffered a midtrimester missed abortion during an acute febrile illness shows the possible systemic effects of infection with Campylobacter jejuni. This "vibrio" was found in blood samples; products of conception were found intact; and evacuation of the uterus led to complete resolution of the infection. Histological examination of the placenta showed that as the infected site, rather than an ascending infection in the maternal genital tract. Pregnancy seems to be a predisposing factor in the occurrence of systemic campylobacter infection.


Assuntos
Aborto Retido/etiologia , Infecções por Campylobacter/complicações , Morte Fetal/etiologia , Complicações Infecciosas na Gravidez , Sepse/complicações , Adulto , Infecções por Campylobacter/terapia , Feminino , Humanos , Gravidez , Primeiro Trimestre da Gravidez , Segundo Trimestre da Gravidez , Sepse/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...